Education
About Us
Working with TipRanks
Follow Us
Nuvectis Pharma (NVCT)
NASDAQ:NVCT
Total Valuation
Nuvectis Pharma has a market cap or net worth of $237.37M. The enterprise value is $205.73M.
Market Cap$237.37M
Enterprise Value$205.73M
Share Statistics
Nuvectis Pharma has 26,491,701 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,491,701
Owned by Insiders42.07%
Owned by Institutions5.52%
Financial Efficiency
Nuvectis Pharma’s return on equity (ROE) is -1.44 and return on invested capital (ROIC) is -149.75%.
Return on Equity (ROE)-1.44
Return on Assets (ROA)-0.83
Return on Invested Capital (ROIC)-149.75%
Return on Capital Employed (ROCE)-1.50
Revenue Per Employee0.00
Profits Per Employee-2.03M
Employee Count13
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nuvectis Pharma is ―. Nuvectis Pharma’s PEG ratio is -0.33.
PE Ratio―
PS Ratio0.00
PB Ratio8.94
Price to Fair Value8.94
Price to FCF-10.29
Price to Operating Cash Flow-12.21
PEG Ratio-0.33
Income Statement
In the last 12 months, Nuvectis Pharma had revenue of 0.00 and earned -26.44M in profits. Earnings per share was -1.32.
Revenue0.00
Gross Profit0.00
Operating Income-27.57M
Pretax Income-26.44M
Net Income-26.44M
EBITDA-27.57M
Earnings Per Share (EPS)-1.32
Cash Flow
In the last 12 months, operating cash flow was -16.01M and capital expenditures 0.00, giving a free cash flow of -16.01M billion.
Operating Cash Flow-16.01M
Free Cash Flow-16.01M
Free Cash Flow per Share-0.60
Dividends & Yields
Nuvectis Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.64
52-Week Price Change17.59%
50-Day Moving Average8.51
200-Day Moving Average7.42
Relative Strength Index (RSI)56.01
Average Volume (3m)89.48K
Important Dates
Nuvectis Pharma upcoming earnings date is May 12, 2026, Before Open (Confirmed).
Last Earnings DateFeb 11, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
Nuvectis Pharma as a current ratio of 2.38, with Debt / Equity ratio of 0.00%
Current Ratio2.38
Quick Ratio2.38
Debt to Market Cap0.00
Net Debt to EBITDA1.15
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Nuvectis Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Nuvectis Pharma EV to EBITDA ratio is -4.83, with an EV/FCF ratio of -8.31.
EV to Sales0.00
EV to EBITDA-4.83
EV to Free Cash Flow-8.31
EV to Operating Cash Flow-8.31
Balance Sheet
Nuvectis Pharma has $31.63M in cash and marketable securities with $0.00 in debt, giving a net cash position of $31.63M billion.
Cash & Marketable Securities$31.63M
Total Debt$0.00
Net Cash$31.63M
Net Cash Per Share$1.19
Tangible Book Value Per Share$0.84
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Nuvectis Pharma is $13.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$13.50
Price Target Upside50.67% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-16.26%